Chemotherapeutics of Visceral Leishmaniasis: present and future developments

Shyam Sundar[*] and **Anup Singh**

Department of Medicine, Institute of Medical Sciences, Banaras Hindu University, Varanasi 221005

SUMMARY

Treatment of Visceral Leishmaniasis (VL), a neglected tropical disease, is very challenging with few treatment options. Long duration of treatment and drug toxicity further limit the target of achieving VL elimination. Chemotherapy remains the treatment of choice. Single dose of liposomal amphotericin B (LAmB) and multidrug therapy (LAmB + miltefosine, LAmB + paromomycin (PM), or miltefosine + PM) are recommended treatment regimen for treatment of VL in Indian sub-continent. Combination therapy of pentavalent antimonials (Sb^v) and PM in East Africa and LAmB in the Mediterranean region/South America remains the treatment of choice. Various drugs having anti-leishmania properties are in preclinical phase and need further development. An effective treatment and secondary prophylaxis of HIV-VL co-infection should be developed to decrease treatment failure and drug resistance.

Keywords

Visceral leishmaniasis; Amphoterecin B; Miltefosine; Paromomycin; Kala-Azar

INTRODUCTION

Visceral leishmaniasis (VL) is one among the various neglected tropical diseases caused by an obligate intracellular protozoan *Leishmania donovani* and transmitted in Indian subcontinent by bite of *Phlebotomus argentipes* (Sand fly) (Singh *et al.*, 2014). Around 0.2 – 0.4 million cases are reported globally. Among these more than 90% of cases are confined to six countries: India, Bangladesh, Sudan, South Sudan, Brazil and Ethiopia (Alvar *et al.*, 2012). A joint memorandum was signed in 2005 by governments of India, Nepal and Bangladesh to eliminate VL with the aim to reduce its incidence by 2015 to less than 1 per 10,000 people at sub-district level. However, this target has been recently extended to 2017 (Singh *et al.*, 2016). Another collaborative disease eradication programme, the London

Declaration on Neglected Tropical Diseases was launched on 30 January 2012 in London. It was inspired by the World Health Organization 2020 roadmap to eradicate or prevent transmission for neglected tropical diseases (London Declaration[*]). The emergence of co-infection with HIV in VL is one of the major challenges which makes treatment more complex and increase the chances of drug resistance. Initially, HIV-VL cases were seen from south-western Europe, but now cases are on increase in Ethiopia, South Asia and Brazil. Co-infection has been reported from more than 35 countries (Alvar *et al.*, 2008; Alvar *et al.*, 1997; Desjeux & Alvar, 2003). The prevalence of human immunodeficiency virus (HIV) in Bihar, India (which, till recently, accounted for 40% of world's burden of VL) is considered low (0.2%–0.3%). Around 2.4% of all VL patients of age 14 years were unknowingly found to be co-infected with HIV in an Indian study (Burza *et al.*, 2014a).

VL clinically manifests as prolonged fever, hepatomegaly, splenomegaly, pancytopenia, progressive anemia and weight loss and is fatal without treatment. About 50% of patients in Sudan and 1 – 3% in India after recovery of VL develop a cutaneous manifestation in form indurated nodules or depigmented macules known as post kala-azar dermal leishmaniasis (PKDL). These cases are difficult to treat and also serve as reservoir of *leishmania* (Mukhopadhyay et al., 2014).

With no effective vaccine available, the only option for treatment of VL remains chemotherapy. With limited inventory of drugs and emerging drug resistance the treatment of VL remains challenging.

Chemotherapy of VL

Pentavalent antimonials (Sb^V)—Sodium stibogluconate (SSG) and meglumine antimoniate (MA) are two forms of available Sb^V. It is given in doses of 20 mg/kg subcutaneously for 28 – 30 days. With emerging resistance to this drug in Bihar and adjoining areas of Nepal alternative treatment strategy has been adopted for these areas (Sundar *et al.*, 2000) (Rijal *et al.*, 2003). Its efficacy has been also found to be low in HIV-VL co-infected patients when compared to immunocompetent VL patients (Ritmeijer *et al.*, 2006a). However, in east Africa SSG monotherapy is still effective with 6 month cure rate of 93.9% (Musa *et al.*, 2012). It was recommended by WHO as first line drug for treatment of VL in east Africa along with combination of SSG-Paromomycin (PM) as the first-line treatment of VL patients in Eastern Africa (WHO report, 2010).

Its use is further limited by associated life threatening toxicities like cardiac arrhythmias, prolonged QT interval (QTc), ventricular premature beats, ventricular tachycardia, ventricular fibrillation and torsades de pointes. Other adverse effects includes arthralgia, myalgia, increased pancreatic and liver enzymes (Sundar & Chakravarty, 2015b).

Amphotericin B and liposomal Amphotericin B—In the Indian subcontinent for treatment of VL, Amphotericin B deoxycholate is recommended at doses of 0.75 – 1.0 mg/kg given for 15 – 20 intravenous infusions. For PKDL, AmB is recommended at a dose

---

[*]**London Declaration** on Neglected Tropical Diseases (http://unitingtocombatntds.org/sites/default/files/resource_file/london_declaration_on_ntds.pdf; accessed 16 March 2015).

of 1 mg/kg/day up to 60 – 80 intravenous infusions for 4 months (Mishra *et al.*, 1992; Thakur, 1997; Thakur *et al.*, 1999). Its toxicity profile includes infusion reactions (in most patients), nephrotoxicity, hypokalemia, myocarditis and occasional death which mandate close monitoring. This along with prolonged hospital stay, escalates the cost of therapy. Lipid formulation of AmB has been developed to minimize side effects and for delivery of drug at large daily doses. Liposomal amphotericin B (AmBisome; Gilead Sciences; LAmB), amphotericin B lipid complex (ABLC; Abelcet, Enzon pharmaceuticals) and amphotericin B colloidal dispersion (ABCD); Amphotec, InterMune Corp.) and several generic formulations are available with LAmB being the only drug which has US FDA approval. Various trials on LAmB has been shown in table 1 Various trials on LAmB has been shown in table 1.

There is considerable geographical variation in the total LAmB dose (Sundar & Chakravarty, 2015b). In the Mediterranean region and South America, 18–21 mg/kg, administered in various regimens, has been recommended (Sundar & Chakravarty, 2015b), (Davidson *et al.*, 1996; Freire *et al.*, 1997; Gradoni *et al.*, 2004; Syriopoulou *et al.*, 2003). Whereas, 10 mg/kg single dose has been shown to cure > 95% VL cases in India (Sundar *et al.*, 2010).. Another study showed that when 20 mg/kg of LAmB was given over 4 – 10 days, relapse rate was 2.4% (Burza *et al.*, 2014b). In Bangladesh, 10 mg/kg single dose of LAmB cured 97% patients (Mondal *et al.*). In another study, LAmB in three doses of 5 mg/kg each (total 15 mg/kg) had cure rate of >95% (Lucero *et al.*, 2015). In Sudan, LAmB is required a much higher dose, when given at 30 mg/kg over 10 days in primary VL cases, showed initial cure rate at 6 months of 92% with treatment failures, deaths and relapses of 1%, 5% and 7% respectively. In relapsed VL cases the initial cure was 94%, treatment failed in 4%, 1% died and 10% relapsed. Six percent were slow responders requiring 50 mg/kg of LAmB (Salih *et al.*, 2014). In Europe, total dose of 18–21 mg/kg is considered adequate (Sundar and Chakravarty, 2013).

However, high cost remains the limiting factor for widespread LAmB use in most of the endemic regions. This was addressed by an agreement for preferential pricing with WHO (agreement between Gilead and WHO for donation of LAmB till 2020) which reduced the price of LAmB to $18 per 50 mg vial for endemic areas of developing countries (Moon *et al.*). Following this, a study was conducted in India in which LAmB was used in a single dose of 10 mg/kg and compared to the conventional AmB administered in 15 infusions of 1 mg/kg, given every other day during a 29 days of treatment. At 6 months, cure rates were comparable in the two groups: 95.7% (95% CI: 93.4–97.9) in the liposomal-therapy group and 96.3% (95% CI: 92.6–99.9) in the conventional-therapy group (Sundar *et al.*, 2010). The decreased treatment cost and hospital stay made liposomal preparation as single infusion an excellent option for treatment of VL in Indian subcontinent. It has been suggested by the WHO Regional Technical Advisory Group (WHO report, 2009) and the WHO Advisory Panel for Leishmaniasis Control (WHO, 2010) to use single dose LAmB as the first line drug for the VL elimination program in the Indian subcontinent. The 10 mg/kg single dose regimen is being used in by the Control Programmes of India, Nepal and Bangladesh.

However, in East Africa low efficacy of LAmB in a randomised controlled trial lead to its midway termination when given as single dose of 7.5, 10 mg/kg body weight, or multiple doses on days 1–5, 14, and 21. Definitive cure at 6 months was 85%, 40% and 58% in

patients treated with multiple doses, and single doses of 7·5 or 10 mg/kg, respectively (Khalil *et al.*, 2014)

An indigenous liposomal amphotericin B (Fungisome, developed by an Indian company Lifecare Innovations, Gurgaon, Haryana, India) was tested in a phase 2 study in two cohorts, cohort 1: 10 mg/kg, cohort 2: 15 mg/kg). Initial cure rate of 100% at day 30 and a definitive cure rate of 93.3% at the 6-month follow-up was achieved in both the cohorts (Sundar *et al.*, 2015).

For HIV-VL co-infection, LAmB is given at a doses of 4 mg/kg for 10 doses (days 1–5, 10, 17, 24, 31 and 38) up to a total dose of 40 mg/kg (WHO report, 2010).. Various trails using LAmB for HIV-VL is shown in table 1.

In a study in Bihar, when intravenous LAmB (20–25 mg/kg) was administered to 159 VL/HIV co-infected patients (both primary infections and relapses) in four or five doses of 5 mg/kg over 4–10 days, the estimated relapse risk at first year, second year and fourth year was 16.1%, 20.4% and 25.9% respectively (Burza *et al.*, 2014a).

In a study in India, excellent initial response was seen with LAmB (a total dose of 20–25 mg/kg in 4–15 days) combined with antiretroviral therapy; however, the probabilities of VL relapse after treatment were 0%, 8.1%, and 26.5% at 6 month, 1 and 2 years respectively (Mahajan *et al.*, 2015). In a retrospective study in Bihar, India, combination of LAmB and miltefosine was tested in 102 HIV-VL co-infected patients. LAmB was given at doses of 30 mg/kg divided in 6 infusions on alternate days, along with oral miltefosine for 14 days. At 6, 12, and 18 months follow-up, the cumulative incidence of all-cause mortality was 11.7%, 14.5%, and 16.6% respectively. Relapse rate were 2.5%, 6.0%, 13.9%, at 6, 12, and 18 month respectively (Mahajan *et al.* 2015). Secondary prophylaxis is also important and found to be effective in HIV-VL co-infected patients as with other opportunistic infections. It has been shown that Amphotericin B lipid complex (3–5 mg/kg per dose once) every 3 weeks for 12 months has 22% relapse rate as comparison to 50% in patients devoid of secondary prophylaxis at one year (Lopez-Velez *et al.*, 2004). LAmB at dose of 5 mg/kg administered every third week has been also studied for use as secondary prophylaxis with relapse free probability of 89.7%, 79.1%, 55.9% and 55.9% at 6, 12 month, 24 and 36 months respectively (Molina *et al.*, 2007). In a retrospective study from eastern India (2005–2015), protective efficacy of monthly amphotericin B (AmB) for secondary prophylaxis in patients with HIV–VL coinfection was done. Secondary prophylaxis was provided in 27 HIV-VL with monthly 1 mg/kg AmB (15 liposomal, 12 deoxycholate). At 6 month, none in secondary prophylaxis group relapsed or died. Secondary prophylaxis remained the sole significant predictor against death in multivariate Cox regression. HIV–VL patients had higher 6-month relapse rate, less relapse-free 12-month survival, and higher mortality than VL mono-infection. (Goswami RP *et al.*).

Miltefosine—Miltefosine, an alkylphospholipid compound, was the first effective oral anti-leishmanial drug in VL. Following a phase III trial, miltefosine was registered in India as first oral antileishmanial drug in 2002. Cure rate of 94% was seen with 50–100 mg/day of miltefosine given for 28 days (Sundar *et al.*, 2002a). Another phase 4 study showed cure rate

of 95% (Bhattacharya *et al.*, 2007). Because of its high efficacy and ease of administration, it was adopted by VL elimination programme in India, Nepal and Bangladesh (Sundar *et al.*, 2008a). Unfortunately, after a decade of its use the efficacy decreased and there was doubling of relapse rate (Burza *et al.*, 2013; Sundar *et al.*, 2012). In Nepal relapse rates of 10.8% and 20% was seen at 6 and 12 months, respectively (Rijal *et al.*, 2013). Cure rate of only 85% and 75.8% was found in studies in Bangladesh and Ethiopia, respectively (Rahman *et al.*, 2011; Ritmeijer *et al.*, 2006b). Similarly for PKDL, miltefosine at doses of 50 mg thrice daily for 60 days or twice daily for 90 days was found to be effective (Ramesh *et al.*, 2011). Another study showed that miltefosine given as 100 mg/day for 12 weeks in PKDL produced high cure rates (Sundar *et al.*, 2013). It is recommended for the treatment of PKDL in the Indian subcontinent at the dose of 50–100 mg for 12 weeks (WHO report, 2010).

Miltefosine is associated with gastrointestinal adverse events chiefly vomiting and diarrhea.. Occasionally hepatotoxicity and nephrotoxicity might occur. It has a long half life (~ one week) which renders it vulnerable for development of its resistance in the parasites. It also has teratogenic potential, so women of child-bearing age are advised contraception for the duration of treatment and for three additional months after the end of therapy. (Sundar & Chakravarty, 2015b).

Paromomycin (aminosidine)—Paromomycin (PM) is an aminoglycoside antibiotic which act by interference with protein synthesis in the ribosome of the target organism and inhibit the respiration (Chawla *et al.*, 2011). In a phase II study of VL patients, PM at dose of 16 mg/kg/day for 21 days led to cure in 93% (Jha *et al.*, 1998). A Phase III trial of PM at a dose of 15 mg/kg (11 mg base) for 21 days showed 95% cure rate (Sundar *et al.*, 2007). PM was approved by the Indian government for VL treatment in Indian subcontinent in August 2006. However, PM was found to be ineffective in curing PKDL with efficacy of only 37.5% (Sundar *et al.*, 2014).

In Bangladesh, in an open label Phase IIIb multicentre study where PM showed cure rate of 94.2% at 6 months when administered at 11 mg/kg (base) intramuscularly once daily for 21 consecutive days (Jamil *et al.*, 2015). In a phase II study in Sudan, Ethiopia and Kenya, its efficacy was low compared to SSG alone and combination of SSG and PM (Hailu *et al.*, 2010). In East Africa, PM efficacy was significantly lower than SSG (84.3% vs 94.1%) in a multi-center randomized-controlled trial (Musa *et al.*, 2012). In Sudan, in a dose-finding phase II study, PM showed efficacy of 80% (95% CI: 56.3 – 94.3%) and 81% (95% CI: 58.1 – 94.6%) when used for a longer duration (15 mg/kg/day for 28 days) or at a higher dose of 20 mg/kg/day for 21 days, respectively (Musa *et al.*, 2010). Pain at the injection site, reversible ototoxicity, and hepatic transaminitis are common adverse effects. Although low cost of PM is an advantage, its parenteral route of administration limits its use in a control program. Monotherapy also pose a danger for development of resistance.

Pentamidine—Pentamidine was used as an alternative treatment for refractory VL in India. However, side effects such as insulin-dependent diabetes mellitus and declining efficacy precludes its further usage (Jha *et al.*, 1991). Injection site pain, indurations and abscess, nausea, vomiting, myalgia, headache, dizziness, hypotension, syncope, transient

hyperglycemia and hypoglycaemia are other adverse effects of this drug (Sundar & Chakravarty, 2015b). It is currently recommended for secondary prophylaxis in HIV-VL co-infection as in a study from Ethiopia revealed relapse-free survival probability of 79% and 71% at 6 months and at 12 months respectively (Diro *et al.*, 2015)

Multidrug therapy—Multidrug therapy advocated for other diseases like malaria, tuberculosis, leprosy, etc. has also been explored for VL treatment. The rationale behind it is to use drugs with synergistic or additive activity making the duration of therapy short with decrease in drug doses which lowers the occurrence of adverse effect and treatment cost (Sundar & Chakravarty, 2015b). Further with monotherapy, there is always a higher chance of development of drug resistance.

In Sudan a study showed initial cure rate of 97% with combination therapy of PM at a dose of 15 mg/kg (equivalent to 11 mg/kg of PM base) plus Sb^v at a dose of 20 mg/kg for 17 days compared to cure rate of 92.4% with Sb^v monotherapy given for 30 days (Melaku *et al.*, 2007). It became the preferred regime in the region following another large multicenter trial which showed comparable efficacy of combination therapy for 17 days with SSG monotherapy (Musa *et al.*, 2012). A prospective pharmacovigilance study sponsored by the Ministries of Health, Médecins Sans Frontières (MSF) and Drugs for Neglected Diseases initiative (DNDi) was recently conducted at 12 centres in cohort from Sudan, Kenya, Uganda and Ethiopia for PM plus Sb^v combination therapy in VL. The initial cure rate was 95.1% with no geographical variation. Thirty four percent (34%) and 1.96% of patients had at least one adverse event (AE) and serious adverse event (SAE) during treatment respectively. Mortality occurred in 1.0% of patients. HIV/VL co-infected patients had initial cure rates of 56 % which was significantly lower than that in VL patients without HIV. (Kimutai *et al.*, 2017)

Combination of miltefosine and LAmB was recently evaluated in Sudan and Kenya where a phase II open-label, non-comparative randomized trial was conducted. Three regimens [10 mg/kg single dose LAmB plus 10 days of SSG (20 mg/kg/day), 10 mg/kg single dose LAmB plus 10 days of miltefosine (2.5 mg/kg/day) and miltefosine alone (2.5 mg/kg/day for 28 days)] were evaluated for efficacy and safety. Although safe, the definitive cure was < 90% in all treatment arms so none regimen was evaluated for phase 3 trials (Wasunna M *et al.*, 2016).

In a multidrug randomized, non-comparative, group-sequential, triangular design study 181 patients were randomly assigned to 5 mg/kg of LAmB alone, 5 mg/kg of LAmB followed by MIL for 10 days or 14 days or 3.75 mg/kg of LAmB followed by miltefosine for 14 days. When efficacy of all regimens was apparant, 5 mg/kg of LAmB followed by miltefosine for 7 days were given 45 additional patients. All groups had similar cure rates (> 95%) (Sundar *et al.*, 2008b).

In a Phase III study in the India, three multidrug regimens were tested (Single injection of 5 mg/kg L AmB and 7-day oral miltefosine or 10-day 11 mg/kg intramuscular PM; or 10 days each of miltefosine and PM). Cure rate of > 97% was found in all the three drug regimens

used (Sundar *et al.*, 2011a). Cure rate of 91.9 % with single dose of LAmB 5 mg/kg with miltefosine 2.5 mg/kg/day for 14 days was shown in another study (Sundar *et al.*, 2011b).

Combination therapy is also attractive option for the treatment of PKDL. (Ramesh V, *et al.*, 2014). Combination therapy is excellent and effective alternative strategy to decrease the cost of therapy by decreasing duration of treatment, side effect associated with drugs and hospital stay. Moreover combination therapy delays drug resistance, thus prolongs use of the drugs.

Newer drugs, Immunotherapy and Vaccine development—The various new compounds at various stages of development have been included in Drugs for Neglected Disease Initiative (DNDi) portfolio as shown in table 2. Each of them is in preclinical stages.

Alternative approach is to use immunotherapy and/or immunochemotherapy against VL. IFN-γ, a cytokine capable has been found to kill intracellular *Leishmania* by activating macrophages (Murray & Cartelli, 1983). Accelerated clearance of parasite is seen on addition of IFN-γ. Treatment of VL with IFN-γ plus Sb^V showed a cure rate of >80% cure rate (Badaro, 1988; Badaro *et al.*, 1990; Sundar *et al.*, 1994). and enhanced the clinical efficacy of conventional Sb^V therapy (Sundar & Murray, 1995). Similarly results were seen in a study in Kenya where Sb^V or Sb^V plus IFN-γ for 30 days was given in two groups for VL treatment with combination therapy showing quick parasite clearance (Squires *et al.*, 1993). In India in a large study, however, low cure rates of 36%, 49% and 42% were obtained at 6 months on treatment with 30 days of Sb^V alone, or 30 days of Sb^V plus IFN-γ at dose of 10^7 U/mg/day, or 15 days of Sb^V plus IFN-γ respectively with maximum efficacy in immunotherapy group (Sundar *et al.*, 1997). Low cure rates in this study led to stoppage of the development of IFN-γ as adjunct to anti-leishmania drugs.

No vaccine is recommended for treatment of VL till now. To be an effective vaccine apart from eliciting prolong immunity it should be protective broadly against VL and CL. Infectious Disease Research Institute (IDRI) has developed vaccines such as Leish-F1, F2 and F3 based on selected *Leishmania* antigen epitopes, and has found to be immunogenic and safe in clinical trials with Leish-F2 completed phase 2 study. The Sabin Vaccine Institute are investigating on the immunogenicity by combination of sand fly salivary gland antigen with the recombinant Leishmania antigens (Chakravarty *et al.*, 2011) (IDRI Vaccine[**]). Recently, a first-in-human dose escalation Phase I trial to assess the safety, tolerability and immunogenicity of a prime-only adenoviral vaccine (ChAd63-KH) was conducted in 20 healthy volunteers for human VL and PKDL. ChAd63-KH was found to be safe and immunogenic and need further development to emerge as a novel third generation vaccine for VL and PKDL (Osman *et al.*, 2017). Various recombinant antigens have been studied to have protective role against *Leishmania* infection however limited to experimental level with minimal experience in preclinical human studies.(Carrillo *et al.*, 2008; Chakravarty *et al.*, 2011; Connell *et al.*, 1993; Gurunathan *et al.*, 1997; Kumar *et al.*, 2010; Noazin *et al.*, 2009; Rafati *et al.*, 2006; Singh *et al.*, 2012; Stober *et al.*, 2005; Sundar & Chakravarty, 2015a)

[**]LEISH-F3 + GLA-SE and the LEISH-F3 + MPL-SE Vaccine. https://clinicaltrials.gov/ct2/show/NCT01751048.

CONCLUSION

With meagre treatment options in chemotherapy and emerging risk of resistance to available drugs, discovery of new drugs with anti-leishmania activity is the need of the hour. Combination therapy of Sb^v with PM and LAmB are recommended in Africa and Mediterranean region respectively. Newer approaches with other drug combination need to be investigated in these different geographical areas. PKDL patients serve as reservoir of infection. Shorter and effective treatment is warranted for success of VL Elimination programme. Drugs for Neglected Diseases Initiative (DNDi) has taken the initiative of finding new novel agents with anti-leishmania agents. Also, feasibility of use of LAmB at district and public health centre in South Asia has also been explored by DNDi. The burden of HIV VL co-infection in increasing and LAmB found effective in Mediterranean region has limited efficacy in Ethiopia having high HIV-VL co-infection burden. Thus newer treatment regimes for this region need to be explored.

Acknowledgments

References

Alvar J, Aparicio P, Aseffa A, Den Boer M, Canavate C, Dedet JP, Gradoni L, Ter Horst R, Lopez-Velez R, Moreno J. The relationship between leishmaniasis and AIDS: the second 10 years. Clinical Microbiology Reviews. 2008; 21:334–59. [PubMed: 18400800]

Alvar J, Canavate C, Gutierrez-Solar B, Jimenez M, Laguna F, Lopez-Velez R, Molina R, Moreno J. Leishmania and human immunodeficiency virus coinfection: the first 10 years. Clinical Microbiology Reviews. 1997; 10:298–319. [PubMed: 9105756]

Alvar J, Velez ID, Bern C, Herrero M, Desjeux P, Cano J, Jannin J, den Boer M. Leishmaniasis worldwide and global estimates of its incidence. PLoS One. 2012; 7:e35671. [PubMed: 22693548]

Badaro R. The use of recombinant gamma interferon associated with pentavalent antimony in therapy for visceral leishmaniasis. Memórias do Instituto Oswaldo Cruz. 1988; 83(Suppl 1):376–7. [PubMed: 3151000]

Badaro R, Falcoff E, Badaro FS, Carvalho EM, Pedral-Sampaio D, Barral A, Carvalho JS, Barral-Netto M, Brandely M, Silva L, et al. Treatment of visceral leishmaniasis with pentavalent antimony and interferon gamma. New England Journal of Medicine. 1990; 322:16–21. [PubMed: 2104665]

Bhattacharya SK, Sinha PK, Sundar S, Thakur CP, Jha TK, Pandey K, Das VR, Kumar N, Lal C, Verma N, Singh VP, Ranjan A, Verma RB, Anders G, Sindermann H, Ganguly NK. Phase 4 trial of miltefosine for the treatment of Indian visceral leishmaniasis. The Journal of Infectious Diseases. 2007; 196:591–8. [PubMed: 17624846]

Burza S, Nabi E, Mahajan R, Mitra G, Lima MA. One-year follow-up of immunocompetent male patients treated with miltefosine for primary visceral leishmaniasis in Bihar, India. Clinical Infectious Diseases. 2013; 57(9):1363–4. [PubMed: 23943824]

Burza S, Mahajan R, Sanz MG, Sunyoto T, Kumar R, Mitra G, Lima MA. HIV and visceral leishmaniasis coinfection in Bihar, India: an underrecognized and underdiagnosed threat against elimination. Clinical Infectious Diseases. 2014a Aug 15; 59(4):552–5. DOI: 10.1093/cid/ciu333 [PubMed: 24814660]

Burza S, Sinha PK, Mahajan R, Lima MA, Mitra G, Verma N, Balasegaram M, Das P. Five-year field results and long-term effectiveness of 20 mg/kg liposomal amphotericin B (Ambisome) for visceral leishmaniasis in Bihar, India. PLOS Neglected Tropical Diseases. 2014b; 8(1):e2603.doi: 10.1371/journal.pntd.0002603 [PubMed: 24392168]

Burza S, Mahajan R, Sinha PK, van Griensven J, Pandey K, Lima MA, Sanz MG, Sunyoto T, et al. Visceral leishmaniasis and HIV co-infection in Bihar, India: long-term effectiveness and treatment outcomes with liposomal amphotericin B (AmBisome). PLOS Neglected Tropical Diseases. 2014c; 8(8):e3053.doi: 10.1371/journal.pntd.0003053 [PubMed: 25101665]

Carrillo E, Crusat M, Nieto J, Chicharro C, Thomas Mdel C, Martinez E, Valladares B, Canavate C, Requena JM, Lopez MC, Alvar J, Moreno J. Immunogenicity of HSP-70, KMP-11 and PFR-2 leishmanial antigens in the experimental model of canine visceral leishmaniasis. Vaccine. 2008; 26:1902–11. [PubMed: 18321614]

Chakravarty J, Kumar S, Trivedi S, Rai VK, Singh A, Ashman JA, Laughlin EM, Coler RN, Kahn SJ, Beckmann AM, Cowgill KD, Reed SG, Sundar S, Piazza FM. A clinical trial to evaluate the safety and immunogenicity of the LEISH-F1+MPL-SE vaccine for use in the prevention of visceral leishmaniasis. Vaccine. 2011; 29:3531–7. [PubMed: 21414377]

Chawla B, Jhingran A, Panigrahi A, Stuart KD, Madhubala R. Paromomycin affects translation and vesicle-mediated trafficking as revealed by proteomics of paromomycin-susceptible-resistant Leishmania donovani. PLoS One. 2011; 6:e26660. [PubMed: 22046323]

Connell ND, Medina-Acosta E, McMaster WR, Bloom BR, Russell DG. Effective immunization against cutaneous leishmaniasis with recombinant bacille Calmette-Guerin expressing the Leishmania surface proteinase gp63. Proceedings of the National Academy of Sciences U S A. 1993; 90:11473–7.

Davidson RN, di Martino L, Gradoni L, Giacchino R, Gaeta GB, Pempinello R, Scotti S, Cascio A, Castagnola E, Maisto A, Gramiccia M, di Caprio D, Wilkinson RJ, Bryceson AD. Short-course treatment of viscera leishmaniasis with liposomal amphotericin B (AmBisome). Clinical Infectious Diseases. 1996; 22(6):938–43. [PubMed: 8783690]

Desjeux P, Alvar J. Leishmania/HIV co-infections: epidemiology in Europe. Annals of Tropical Medicine & Parasitology. 2003; 97(Suppl 1):3–15. [PubMed: 14678629]

Di M F, Ursini T, Iannece MD, Chianura L, Baldasso F, Foti G, Di G P, Casabianca A, Storaci N, Nigro L, Colomba C, Marazzi M G, Todaro G, Tordini G, Zanelli G, Cenderello G, Acone N, Polilli E, Migliore S, Almi P, Pizzigallo E, Sagnelli E, Mazzotta F, Russo R, Manzoli L, Parruti G. Five-year retrospective Italian multicenter study of visceral leishmaniasis treatment. antimicrob Agents Chemother. 2014; 58(1):414–8. [PubMed: 24189252]

Diro E, Ritmeijer K, Boelaert M, Alves F, Mohammed R, Abongomera C, Ravinetto R, De C M, Fikre H, Adera C, Colebunders R, van L H, Menten J, Lynen L, Hailu A, van G J. Use of Pentamidine As Secondary Prophylaxis to Prevent Visceral Leishmaniasis Relapse in HIV Infected Patients, the First Twelve Months of a Prospective Cohort Study. PLOS Neglected Tropical Diseases. 2015; 2(10):e0004087. 9.

Freire M, Badaró F, Avelar ME, Luz K, Nakatani MS, Teixeira R EMN, Badaró R. Efficacy and tolerability of liposomal amphotericin B (Ambisome) in th treatment of visceral leishmaniasis i Brazil. Brazilian Journal of Infectious Diseases. 1997; 1(5):230–240. [PubMed: 11105143]

Goswami RP, Basu A, Ray Y, Rahman M, Tripathi SK. Protective Efficacy of Secondary Prophylaxis Against Visceral Leishmaniasis in Human Immunodeficiency Virus Coinfected Patients Over the Past 10 Years in Eastern India. The American Journal of Tropical Medicine and Hygiene. 2017; 8(2):285–291. 96.

Gradoni L, Gramiccia M, Scalone A. Change in human visceral leishmaniasi treatment in Italy: retrospective study of 630 patients. Parassitologia. 2004; 46(1–2):199–201. [PubMed: 15305716]

Gurunathan S, Sacks DL, Brown DR, Reiner SL, Charest H, Glaichenhaus N, Seder RA. Vaccination with DNA encoding the immunodominant LACK parasite antigen confers protective immunity to mice infected with Leishmania major. The Journal of Experimental Medicine. 1997; 186:1137–47. [PubMed: 9314562]

Hailu A, Musa A, Wasunna M, Balasegaram M, Yifru S, Mengistu G, Hurissa Z, Hailu W, Weldegebreal T, Tesfaye S, Makonnen E, Khalil E, Ahmed O, Fadlalla A, El-Hassan A, Raheem M, Mueller M, Koummuki Y, Rashid J, Mbui J, Mucee G, Njoroge S, Manduku V, Musibi A, Mutuma G, Kirui F, Lodenyo H, Mutea D, Kirigi G, Edwards T, Smith P, Muthami L, Royce C, Ellis S, Alobo M, Omollo R, Kesusu J, Owiti R, Kinuthia J. Geographical variation in the response of visceral leishmaniasis to paromomycin in East Africa: a multicentre, open-label, randomized trial. PLOS Neglected Tropical Diseases. 2010; 4:e709. [PubMed: 21049059]

Jamil K M, Haque R, Rahman R, Faiz M A, Bhuiyan A T, Kumar A, Hassan S M, Kelly H, Dhalaria P, Kochhar S, Desjeux P, Bhuiyan M A, Khan M M, Ghosh R S. Effectiveness Study of Paromomycin IM Injection (PMIM) for the Treatment of Visceral Leishmaniasis (VL) in Bangladesh. PLOS Neglected Tropical Diseases. 2015; 23(10):e0004118. 9.

Jha SN, Singh NK, Jha TK. Changing response to diamidine compounds in cases of kala-azar unresponsive to antimonial. The Journal of the Association of Physicians of India. 1991; 39:314–6. [PubMed: 1938817]

Jha TK, Olliaro P, Thakur CP, Kanyok TP, Singhania BL, Singh IJ, Singh NK, Akhoury S, Jha S. Randomised controlled trial of aminosidine (paromomycin) v sodium stibogluconate for treating visceral leishmaniasis in North Bihar, India. British Medical Journal. 1998; 316:1200–5. [PubMed: 9583927]

Khalil E A, Weldegebreal T, Younis B M, Omollo R, Musa A M, Hailu W, Abuzaid A A, Dorlo T P, Hurissa Z, Yifru S, Haleke W, Smith P G, Ellis S, Balasegaram M, EL-Hassan A M, Schoone G J, Wasunna M, Kimutai R, Edwards T, Hailu A. Safety and efficacy of single dose versus multiple doses of AmBisome for treatment of visceral leishmaniasis in eastern Africa: a randomised trial. PLOS Neglected Tropical Diseases. 2014; 16(1):e2613. 8.

Kimutai R, Musa A M, Njoroge S, Omollo R, Alves F, Hailu A, Khalil E A, Diro E, Soipei P, Musa B, Salman K, Ritmeijer K, Chappuis F, Rashid J, Mohammed R, Jameneh A, Makonnen E, Olobo J, Okello L, Sagaki P, Strub N, Ellis S, Alvar J, Balasegaram M, Alirol E, Wasunna M. Safety and Effectiveness of Sodium Stibogluconate and Paromomycin Combination for the Treatment of Visceral Leishmaniasis in Eastern Africa: Results from a Pharmacovigilance Programme. Clinical Drug Investigation. 2017; 37(3):259–272. [PubMed: 28066878]

Kumar R, Goto Y, Gidwani K, Cowgill KD, Sundar S, Reed SG. Evaluation of ex vivo human immune response against candidate antigens for a visceral leishmaniasis vaccine. The American Journal of Tropical Medicine and Hygiene. 2010; 82:808–13. [PubMed: 20439959]

Lopez-Velez R, Videla S, Marquez M, Boix V, Jimenez-Mejias ME, Gorgolas M, Arribas JR, Salas A, Laguna F, Sust M, Canavate C, Alvar J. Amphotericin B lipid complex versus no treatment in the secondary prophylaxis of visceral leishmaniasis in HIV-infected patients. Journal of Antimicrobial Chemotherapy. 2004; 53:540–3. [PubMed: 14739148]

Lucero E, Collin SM, Gomes S, Akter F, Asad A AKD, Ritmeijer K. Effectiveness and Safety of Short Course Liposomal Amphotericin B (AmBisome) as First Line Treatment for Visceral Leishmaniasis in Bangladesh. PLOS Neglected Tropical Diseases. 2015; eCollection 2015. doi: 10.1371/journal.pntd.0003699

Mahajan R, Das P, Isaakidis P, Sunyoto T, Sagili K D, Lima M A, Mitra G, Kumar D, Pandey K, Van G JP, Boelaert M, Burza S. Combination Treatment for Visceral Leishmaniasis Patients Coinfected with Human Immunodeficiency Virus in India. clinical Infectious Diseases. 2015; 61(8):1255–62. [PubMed: 26129756]

Melaku Y, Collin SM, Keus K, Gatluak F, Ritmeijer K, Davidson RN. Treatment of kala-azar in southern Sudan using a 17-day regimen of sodium stibogluconate combined with paromomycin: a retrospective comparison with 30-day sodium stibogluconate monotherapy. The American Journal of Tropical Medicine and Hygiene. 2007; 77:89–94. [PubMed: 17620635]

Mishra M, Biswas UK, Jha DN, Khan AB. Amphotericin versus pentamidine in antimony-unresponsive kala-azar. Lancet. 1992; 340(8830):1256–7. [PubMed: 1359322]

Musa, A., Khalil, E. Drugs for Neglected Diseases. Vol. 22. Doka, Gedaref; Sudan: 2015. Phase II proof of concept trial to determine efficacy of fexinidazole in visceral leishmaniasis patients in Sudan.

Molina I, Falco V, Crespo M, Riera C, Ribera E, Curran A, Carrio J, Diaz M, Villar del Saz S, Fisa R, Lopez-Chejade P, Ocana I, Pahissa A. Efficacy of liposomal amphotericin B for secondary prophylaxis of visceral leishmaniasis in HIV-infected patients. Journal of Antimicrobial Chemotherapy. 2007; 60:837–42. [PubMed: 17684055]

Mondal D, Alvar J, Hasnain MG, Hossain MS, Ghosh D, Huda MM, Nabi SG, Sundar S, Matlashewski G, Arana B. Efficacy and safety of single-dose liposomal amphotericin B for visceral leishmaniasis in a rural public hospital in Bangladesh: a feasibility study. Lancet Glob Health. 2:e51–7. [PubMed: 25104636]

Moon S, Jambert E, Childs M, von Schoen-Angerer T. A win-win solution?: A critical analysis of tiered pricing to improve access to medicines in developing countries. Global Health. 7:39. [PubMed: 21992405]

Mukhopadhyay D, Dalton JE, Kaye PM, Chatterjee M. Post kala-azar dermal leishmaniasis: an unresolved mystery. Trends Parasitol. 2014; 30(2):65–74. DOI: 10.1016/j.pt.2013.12.004 [PubMed: 24388776]

Murray HW, Cartelli DM. Killing of intracellular Leishmania donovani by human mononuclear phagocytes. Evidence for oxygen-dependent and -independent leishmanicidal activity. The Journal of Clinical Investigation. 1983; 72:32–44. [PubMed: 6308049]

Musa A, Khalil E, Hailu A, Olobo J, Balasegaram M, Omollo R, Edwards T, Rashid J, Mbui J, Musa B, Abuzaid AA, Ahmed O, Fadlalla A, El-Hassan A, Mueller M, Mucee G, Njoroge S, Manduku V, Mutuma G, Apadet L, Lodenyo H, Mutea D, Kirigi G, Yifru S, Mengistu G, Hurissa Z, Hailu W, Weldegebreal T, Tafes H, Mekonnen Y, Makonnen E, Ndegwa S, Sagaki P, Kimutai R, Kesusu J, Owiti R, Ellis S, Wasunna M. Sodium stibogluconate (SSG) & paromomycin combination compared to SSG for visceral leishmaniasis in East Africa: a randomised controlled trial. PLOS Neglected Tropical Diseases. 2012; 6:e1674. [PubMed: 22724029]

Musa AM, Younis B, Fadlalla A, Royce C, Balasegaram M, Wasunna M, Hailu A, Edwards T, Omollo R, Mudawi M, Kokwaro G, El-Hassan A, Khalil E. Paromomycin for the treatment of visceral leishmaniasis in Sudan: a randomized, open-label, dose-finding study. PLOS Neglected Tropical Diseases. 2010; 4:e855. [PubMed: 21049063]

Noazin S, Khamesipour A, Moulton LH, Tanner M, Nasseri K, Modabber F, Sharifi I, Khalil EA, Bernal ID, Antunes CM, Smith PG. Efficacy of killed whole-parasite vaccines in the prevention of leishmaniasis: a meta-analysis. Vaccine. 2009; 27:4747–53. [PubMed: 19540273]

Osman M, Mistry A, Keding A, Gabe R, Cook E, Forrester S, et al. A third generation vaccine for human visceral leishmaniasis and post kala azar dermal leishmaniasis: First-in-human trial of ChAd63-KH. PLOS Neglected Tropical Diseases. 2017 May 12.11(5):e0005527.doi: 10.1371/journal.pntd.0005527 [PubMed: 28498840]

Rafati S, Zahedifard F, Nazgouee F. Prime-boost vaccination using cysteine proteinases type I and II of Leishmania infantum confers protective immunity in murine visceral leishmaniasis. Vaccine. 2006; 15(12):2169–75. 24.

Rahman M, Ahmed BN, Faiz MA, Chowdhury MZ, Islam QT, Sayeedur R, Rahman MR, Hossain M, Bangali AM, Ahmad Z, Islam MN, Mascie-Taylor CG, Berman J, Arana B. Phase IV trial of miltefosine in adults and children for treatment of visceral leishmaniasis (kala-azar) in Bangladesh. The American Journal of Tropical Medicine and Hygiene. 2011; 85:66–9. [PubMed: 21734127]

Ramesh V, Katara GK, Verma S, Salotra P. Miltefosine as an effective choice in the treatment of post-kala-azar dermal leishmaniasis. British Journal of Dermatology. 2011; 165:411–4. [PubMed: 21561437]

Ramesh V, Avishek K, Sharma V, Salotra P. Combination therapy with amphotericin-B and miltefosine for post-kala-azar dermal leishmaniasis: a preliminary report. Acta Derm Venereol. 2014; 94:242–243. [PubMed: 23995012]

Rijal S, Chappuis F, Singh R, Bovier PA, Acharya P, Karki BM, Das ML, Desjeux P, Loutan L, Koirala S. Treatment of visceral leishmaniasis in south-eastern Nepal: decreasing efficacy of sodium stibogluconate and need for policy to limit further decline. Transactions of the Royal Society of Tropical Medicine and Hygiene. 2003; 97(3):350–4. [PubMed: 15228258]

Rijal S, Ostyn B, Uranw S, Rai K, Bhattarai NR, Dorlo TPC, Beijnen JH, Vanaerschot M, Decuypere S, Dhakal SS, Das ML, Karki P, Singh R, Boelaert M, Dujardin JC. Increasing Failure of Miltefosine in the Treatment of Kala-azar in Nepal and the Potential Role of Parasite Drug Resistance, Reinfection, or Noncompliance. Clinical Infectious Diseases. 2013; 56:1530–1538. [PubMed: 23425958]

Ritmeijer K, Dejenie A, Assefa Y, Hundie TB, Mesure J, Boots G, den Boer M, Davidson RN. A comparison of miltefosine and sodiu stibogluconate for treatment of visceral leishmaniasis in an Ethiopian population with high prevalence of HIV infection. Clinical Infectious Diseases. 2006 Aug 1; 43(3):357–64. [PubMed: 16804852]

Ritmeijer K, ter Horst R, Chane S, Aderie EM, Piening T, Collin SM, et al. Limited effectiveness of high-dose liposomal amphotericin B (AmBisome) for treatment of visceral leishmaniasis in an Ethiopian population with high HIV prevalence. Clinical Infectious Diseases. 2011 Dec; 53(12):e152–8. [PubMed: 22016502]

Russo R, Nigro L C, Minniti S, Montineri A, Gradoni L, Caldeira L, Davidson R N. Visceral leishmaniasis in HIV infected patients: treatment with high dose liposomal amphotericin B (AmBisome). Journal of Infection. 1996; 32(2):133–7. [PubMed: 8708370]

Salih NA, van Griensven J, Chappuis F, Antierens A, Mumina A, Hammam O, Boulle P, Alirol E, Alnour M, Elhag MS, Manzi M, Kizito W, Zachariah R. Liposomal amphotericin B for complicated visceral leishmaniasi (kala-azar) in eastern Sudan: how effective is treatment for this neglecte disease? Search Results Tropical Medicine & International Health. 2014; Epub 2014 Jan 17. doi: 10.1111/tmi.12238

Singh OP, Hasker E, Boelaert M, Sundar S. Elimination of visceral leishmaniasis on the Indian subcontinent. The Lancet Infectious Diseases. 2016 Dec; 16(12):e304–e309. [PubMed: 27692643]

Singh OP, Hasker E, Sacks D, Boelaert M, Sundar S. Asymptomatic Leishmania Infection: A New Challenge for Leishmania Control. Clinical Infectious Diseases. 2014 May; 58(10):1424–9. 2014. [PubMed: 24585564]

Singh OP, Stober CB, Singh AK, Blackwell JM, Sundar S. Cytokine responses to novel antigens in an Indian population living in an area endemic for visceral leishmaniasis. PLOS Neglected Tropical Diseases. 2012; 6:e1874. [PubMed: 23150744]

Sinha PK, Roddy P, Palma PP, Kociejowski A, Lima MA, Rabi Das VN, Gupta J, Kumar N, Mitra G, Saint-Sauveur JF, Seena S, Balasegaram M, Parreno F, Pandey K. Effectiveness and safety of liposomal amphotericin B for visceral leishmaniasis under routine program conditions in Bihar, India. American Journal of Tropical Medicine and Hygiene. 2010; 83:357–364. [PubMed: 20682882]

Sinha PK, van Griensven J, Pandey K, Kumar N, Verma N, Mahajan R, Kumar P, Kumar R, Das P, Mitra G, Flevaud L, Ferreyra C, Remartinez D, Pece M, Palma PP. Liposomal amphotericin B for visceral leishmaniasis in human immunodeficiency virus-coinfected patients: 2-year treatment outcomes in Bihar, India. Clinical Infectious Diseases. 2011; 53(7):e91–8. DOI: 10.1093/cid/cir521 [PubMed: 21890763]

Squires K E, Rosenkaimer F, Sherwood J A, Forni A L, Were J B, Murray H W. Immunochemotherapy for visceral leishmaniasis: a controlled pilot trial of antimony versus antimony plus interferon-gamma. American Journal of Tropical Medicine and Hygiene. 1993; 48(5):666–9. [PubMed: 8390795]

Stober CB, Lange UG, Roberts MT, Alcami A, Blackwell JM. IL-10 from regulatory T cells determines vaccine efficacy in murine Leishmania major infection. The Journal of Immunology. 2005; 175:2517–24. [PubMed: 16081824]

Sundar S, Agrawal G, Rai M, Makharia MK, Murray HW. Treatment of Indian visceral leishmaniasis with single or daily infusions of low dose liposomal amphotericin B: randomised trial. British Medical Journal. 2001; 323:419–422. [PubMed: 11520836]

Sundar S, Agrawal N, Arora R, Agarwal D, Rai M, Chakravarty J. Short-course paromomycin treatment of visceral leishmaniasis in India: 14-day vs 21-day treatment. Clinical Infectious Diseases. 2009; 49:914–8. [PubMed: 19663597]

Sundar S, Chakravarty J. Leishmaniasis: an update of current pharmacotherapy. Expert Opinion on Pharmacotherapy. 2013 Jan; 14(1):53–63. [PubMed: 23256501]

Sundar S, Chakravarty J. Investigational drugs for visceral leishmaniasis. Expert Opinion on Investigational Drugs. 2015a; 24(1):43–59. [PubMed: 25409760]

Sundar S, Chakravarty J. An update on pharmacotherapy for leishmaniasis. Expert Opinion on Pharmacotherapy. 2015b:1–16. [PubMed: 25387541]

Sundar S, Chakravarty J, Agarwal D, Rai M, Murray HW. Single-dose liposomal amphotericin B for visceral leishmaniasis in India. The New England Journal of Medicine. 2010; 362:504–12. [PubMed: 20147716]

Sundar S, Jha TK, Thakur CP, Engel J, Sindermann H, Fischer C, Junge K, Bryceson A, Berman J. Oral miltefosine for Indian visceral leishmaniasis. The New England Journal of Medicine. 2002a; 347:1739–46. [PubMed: 12456849]

Sundar S, Jha TK, Thakur CP, Mishra M, Singh VP, Buffels R. Low-dose liposomal amphotericin B in refractory Indian visceral leishmaniasis: a multicenter study. American Journal of Tropical Medicine and Hygiene. 2002b; 66:143–146. [PubMed: 12135284]

Sundar S, Jha TK, Thakur CP, Sinha PK, Bhattacharya SK. Injectable paromomycin for Visceral leishmaniasis in India. The New England Journal of Medicine. 2007; 356:2571–81. [PubMed: 17582067]

Sundar S, Jha TK, Thakur CP, Mishra M, Singh VP, Buffels R. Single-dose liposomal amphotericin B in the treatment of visceral leishmaniasis in India: a multicenter study. Clinical Infectious Diseases. 2003; 37:800–804. [PubMed: 12955641]

Sundar S, Mondal D, Rijal S, Bhattacharya S, Ghalib H, Kroeger A, Boelaert M, Desjeux P, Richter-Airijoki H, Harms G. Implementation research to support the initiative on the elimination of kala azar from Bangladesh, India and Nepal--the challenges for diagnosis and treatment. Tropical Medicine and International Health. 2008a; 13:2–5. [PubMed: 18290995]

Sundar S, Rai M, Chakravarty J, Agarwal D, Agrawal N, Vaillant M, Olliaro P, Murray HW. New treatment approach in Indian visceral leishmaniasis: single-dose liposomal amphotericin B followed by short-course oral miltefosine. Clinical Infectious Diseases. 2008b; 47:1000–6. [PubMed: 18781879]

Sundar S, More DK, Singh MK, Singh VP, Sharma S, Makharia A, Kumar PC, Murray HW. Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the Indian epidemic. Clinical Infectious Diseases. 2000; 31:1104–7. [PubMed: 11049798]

Sundar S, Murray HW. Effect of treatment with interferon-gamma alone in visceral leishmaniasis. The Journal of Infectious Diseases. 1995; 172:1627–9. [PubMed: 7594733]

Sundar S, Rosenkaimer F, Murray HW. Successful treatment of refractory visceral leishmaniasis in India using antimony plus interferon-gamma. The Journal of Infectious Diseases. 1994; 170:659–62. [PubMed: 8077725]

Sundar S, Singh A, Rai M, Chakravarty J. Single-Dose Indigenous Liposomal Amphotericin B in the Treatment of Indian Visceral Leishmaniasis: A Phase 2 Study. The American Journal of Tropical Medicine and Hygiene. 2015; Epub 2014 Dec 15. doi: 10.4269/ajtmh.14-0259

Sundar S, Singh A, Rai M, Prajapati VK, Singh AK, Ostyn B, Boelaert M, Dujardin JC, Chakravarty J. Efficacy of miltefosine in the treatment of visceral leishmaniasis in India after a decade of use. Clinical Infectious Diseases. 2012; 55:543–50. [PubMed: 22573856]

Sundar S, Singh A, Tiwari A, Shukla S, et al. Efficacy and Safety of Paromomycin in Treatment of Post-Kala-Azar Dermal Leishmaniasis. ISRN Parasitology. 2014; 2014:4. Article ID 548010.

Sundar S, Singh VP, Sharma S, Makharia MK, Murray HW. Response to interferon-gamma plus pentavalent antimony in Indian visceral leishmaniasis. The Journal of Infectious Diseases. 1997; 176:1117–9. [PubMed: 9333181]

Sundar S, Sinha P, Jha TK, Chakravarty J, Rai M, Kumar N, Pandey K, Narain MK, Verma N, Das VN, Das P, Berman J, Arana B. Oral miltefosine for Indian post-kala-azar dermal leishmaniasis: a randomised trial. Tropical Medicine & International Health. 2013; 18:96–100. [PubMed: 23136856]

Sundar S, Sinha PK, Rai M, Verma DK, Nawin K, Alam S, Chakravarty J, Vaillant M, Verma N, Pandey K, Kumari P, Lal CS, Arora R, Sharma B, Ellis S, Strub-Wourgaft N, Balasegaram M, Olliaro P, Das P, Modabber F. Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: an open-label, non-inferiority, randomised controlled trial. Lancet. 2011a; 377:477–86. [PubMed: 21255828]

Sundar S, Sinha PK, Verma DK, Kumar N, Alam S, Pandey K, Kumari P, Ravidas V, Chakravarty J, Verma N, Berman J, Ghalib H, Arana B. Ambisome plus miltefosine for Indian patients with kala-azar. Transactions of the Royal Society of Tropical Medicine and Hygiene. 2011b; 105:115–7. [PubMed: 21129762]

Syriopoulou V, Daikos GL, Theodoridou M, Pavlopoulou I, Manolaki AG, Sereti E, Karamboula A, Papathanasiou D, Krikos X, Saroglou G. Two doses of lipid formulation of amphotericin B for the

treatment of Mediterranean viscera leishmaniasis. Clinical Infectious Diseases. 2003; 36(5):560–6. Epub 2003 Feb 17. [PubMed: 12594635]

Thakur CP. A comparison of intercostal and abdominal routes of splenic aspiration and bone marrow aspiration in the diagnosis of visceral leishmaniasis. Transactions of the Royal Society of Tropical Medicine and Hygiene. 1997 Nov-Dec;91(6):668–70. [PubMed: 9509175]

Thakur CP. A single high dose treatment of kala-azar with Ambisome (amphotericin B lipid complex): a pilot study. International Journal of Antimicrobial Agents. 2001; 17:67–70. [PubMed: 11137652]

Thakur CP, Pandey AK, Sinha GP, Roy S, Behbehani K, Olliaro P. Comparison of three treatment regimens with liposomal amphotericin B (AmBisome) for visceral leishmaniasis in India: a randomized dose-finding study. Transactions of the Royal Society of Tropical Medicine and Hygiene. 1996; 90:319–322. [PubMed: 8758093]

Thakur CP, Singh RK, Hassan SM, Kumar R, Narain S, Kumar A. Amphotericin B deoxycholate treatment of visceral leishmaniasis with newer modes of administration and precautions: a study of 938 cases. Transactions of the Royal Society of Tropical Medicine and Hygiene. 1999 May-Jun; 93(3):319–23. [PubMed: 10492770]

Wasunna M, Njenga S, Balasegaram M, Alexander N, Omollo R, Edwards T, et al. Efficacy and Safety of AmBisome in Combination with Sodium Stibogluconate or Miltefosine and Miltefosine Monotherapy for African Visceral Leishmaniasis: Phase II Randomized Trial. PLoS Neglected Tropical Diseases. 2016; 10(9):e0004880. http://doi.org/10.1371/journal.pntd.0004880. [PubMed: 27627654]

World Health Organisation. Report of the 3rd Meeting. Dhaka; Bangladesh: 2009. Regional Technical Advisory Group on Kala-azar elimination.

World Health Organization. Report of a meeting of the WHO Expert Committee on the Control of Leishmaniases. World Health Organization; Geneva, Switzerland: 2010. Control of the Leishmaniasis.

World Health Organization. World Health Organization Technical Report Series. World Health Organization; Geneva, Switzerland: 2014. WHO Expert Committee on Specifications for Pharmaceutical Preparations; p. 1-387.back cover

Department of AIDS Control, NACO. [Accessed 10 august 2016] Ministry of Health and family Welfare Government of India. State HIV Epidemic Fact Sheets. Jul, 2014. Available at: http://www.naco.gov.in/upload/2014mslns/STATEHIVEPIDEMICFACTSHEET.pdf

Table 1

L-AmB trials in VL and HIV-VL co-infection

Serial no.	Type of study	Author	Dose used	Overall cure rate percentage	Disease
1	Randomized open study	Thakur *et al.*, 1996	2 mg/kg/day on day 1, 2, 3, 4, 5, 6 and 10 vs. days 1, 2, 3, 4 and 10	100%	VL
2	Randomised	Thakur, 2001	15 mg/kg single dose (i.v)	100%	VL
3	Open label, dose finding	Sundar *et al.*, 2001	5 mg/kg (single dose) vs. 1 mg/kg for 5 days (iv)	91% vs 93%	VL
4	Randomized, dose ranging, multicentre	Sundar *et al.*, 2002b	0.75 mg/kg/days for 5 days (i.v) vs 1.5 mg/kg/days for 5 days (i.v) vs 3 mg/kg/days for 5 days (i.v)	89% vs 93% vs 96%	VL
5	Open label non comparative study	Sundar *et al.*, 2003	5.0 mg/kg/days for 5 days (i.v)	90%	VL
6	Observational cohort	Sinha *et al.*, 2010	5.0 mg/kg/day (i.v) on 0, 1, 4, and 9	98.8%	VL
7	Retrospective, multicentre	Di Masi *et al.*, 2014	Variable (40.8 ± 6.7 mg/kg for 12.0 ± 3.4 days)	72%	HIV-VL
8	Retrospective, non-comparative, multicentre	Sinha *et al.*, 2011	20 – 25 mg/kg on day 1, 2, 5, 10, 15 (5th dose for relapsed cases)	78.2%	HIV-VL
9	Retrospective, non-comparative, multicentre	Ritmeijer *et al.*, 2011	30 mg/kg in 6 doses of 5 mg/kg alternate day	66.1%	HIV-VL
10	Prospective non-comparative, multicentre	Russo *et al.*, 1996	4 mg/kg for 10 doses (days 1 – 5, 10, 17, 24, 31 and 39)	80%	HIV-VL
11	Prospective, non-comparative, single centre	Molina *et al.*, 2007	4 mg/kg/day for 5 days followed by one per week for 5 weeks	50%	HIV-VL

Table 2

Newer compounds in pipeline for Visceral leishmaniasis in various stages of development:

Serial no.	Drugs/compound	Stage of Development	Reference
1	Nitroimidazooxazine (DNDi-0690)	Translation phase	DNDi (2017) leishmaniasis portfolio
2	Oxaboroles (DNDi-5421 and DNDi-5610)	Lead optimisation	
3	Oxaboroles (DNDi-6148)	Translation phase	
4	CGH VL Series 1	Lead optimisation	
5.	Aminopyrazoles	Lead optimisation	